Latest News about GSK
Recent news which mentions GSK
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
May 12, 2023
Tickers
GSK
From Benzinga
From Benzinga
From Benzinga
From Motley Fool
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
May 08, 2023
From Benzinga
From Benzinga
KVUE Stock: Should You Buy Into the Kenvue IPO?
May 03, 2023
From InvestorPlace
From Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
April 27, 2023
From InvestorPlace
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
April 27, 2023
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
From Benzinga
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
From Motley Fool
Was This Acquisition a Savvy Play by This Big Pharma Stock?
April 26, 2023
From Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
April 25, 2023
From Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
From Motley Fool
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
From Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
From Benzinga
Why Shares of Bellus Health Skyrocketed This Week
April 20, 2023
From Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
April 18, 2023
From Motley Fool
From Benzinga
Bellus Health’s stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
April 18, 2023
From MarketWatch
Why Is Bellus Health (BLU) Stock Up 98% Today?
April 18, 2023
From InvestorPlace
From MarketWatch
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
April 18, 2023
From Benzinga
GSK to acquire U.S.-based BELLUS Health for $14.75 per share
April 18, 2023
From MarketWatch
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
April 13, 2023
From Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
